Device Wound Care

Puraply Franchise

Payments companies reported to CMS as associated with Puraply Franchise. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$14Kassociated payments (2023-2025)

371clinicians with associated payments

1company reporting

By year

2024 $14K

Payments reported as associated with Puraply Franchise, per program year, as reported to CMS.

Who makes it

Organogenesis INC. $14K associated with Puraply Franchise (2023-2025)

Specialties most often involved

Foot & Ankle Surgery $2,299

Surgery $1,436

Family $1,394

Podiatrist $1,266

Plastic Surgery $755

Plastic and Reconstructive Surgery $747

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Puraply Franchise

These are the largest totals companies reported as associated with Puraply Franchise. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
James Wang	Chicago, IL	Facial Plastic Surgery	$235.82
Kevin Jeong	Brooklyn, NY	Podiatrist	$197.68
John Hoina	Plainview, NY	Foot & Ankle Surgery	$197.68
Robert Cooper	Rockville Centre, NY	Plastic and Reconstructive Surgery	$197.68
Dominic Ricciardi	Las Vegas, NV	Internal Medicine	$157.10
Gagandeep Sandhu	Chicago, IL	Foot & Ankle Surgery	$156.51
Nathaniel George	Chicago, IL	Podiatrist	$153.86
Christopher Lumley	Bingham Farms, MI	Plastic and Reconstructive Surgery	$142.86
Michael Busuito	Troy, MI	Plastic Surgery	$142.86
Babak Sadri	Allentown, PA	Surgery	$142.86

Prescribed Puraply Franchise?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.